Communiqués RAPT Therapeutics, Inc.

Actions

RAPT

US75382E2081

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 02/03/2026			Varia. 5j.	Varia. 1 janv.
58,02 ^USD	+0,07%		-.--%	+71,30%

04/03	GSK a finalisé l'acquisition de RAPT Therapeutics
03/03	Levée de fonds pour Rosebank ; Surface Transforms perd son contrat avec GM	AN

Communiqués

12/02	Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders?	PR
12/02	Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders?	PR
06/02	Halper Sadeh LLC is Investigating Whether NWE, DHIL, RAPT are Obtaining Fair Prices for its Shareholders	PR
05/02	RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT	BU
21/01	RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT	BU
21/01	GSK to acquire California biotech group for $2.2bn	AQ
21/01	Halper Sadeh LLC Encourages CVGW, RAPT, CFLT Shareholders to Contact the Firm to Discuss Their Rights	PR
07/01	RAPT Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference	AQ
06/11	RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights	AQ
04/11	RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences	AQ
27/10/25	RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies	AQ
22/10/25	RAPT Therapeutics Announces Pricing of Public Offering of Common Stock	AQ
21/10/25	RAPT Therapeutics Announces Proposed Public Offering of Common Stock	AQ
20/10/25	RAPT Therapeutics : October 2025 Corporate Presentation	PU
20/10/25	RAPT Therapeutics and Shanghai Jeyou Pharmaceutical Announce Positive Topline Data from Phase 2 Trial of RPT904 (JYB1904) in Chronic Spontaneous Urticaria	AQ
19/10/25	RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)	AQ
29/09/25	RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy	AQ
27/08/25	RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences	AQ
07/08/25	RAPT Therapeutics Reports Second Quarter 2025 Financial Results	AQ
23/06/25	RAPT Therapeutics Names Two Industry Veterans to its Board of Directors	AQ
13/06/25	RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split	GL
13/06/25	RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split	AQ
04/06/25	RAPT Therapeutics to Participate in Upcoming Investor Conferences	GL
04/06/25	RAPT Therapeutics to Participate in Upcoming Investor Conferences	AQ
08/05/25	RAPT Therapeutics Reports First Quarter 2025 Financial Results	GL